Growth in the concurrent use of antipsychotics with other psychotropic medications in medicaid-enrolled children

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 53, Issue 9, 2014, Pages

  Kreider, Amanda R ^a   Matone, Meredith ^a   Bellonci, Christopher ^b   Dosreis, Susan ^c   Feudtner, Chris ^d   Huang, Yuan Shung ^a   Localio, Russell ^e   Rubin, David M ^d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

foster care; Medicaid; pediatric psychopharmacology; polypharmacy; second generation antipsychotics

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; SECOND GENERATION ANTIPSYCHOTIC AGENT; UNCLASSIFIED DRUG; PSYCHOTROPIC AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD HEALTH CARE; CROSS-SECTIONAL STUDY; DISABILITY; DRUG UTILIZATION; FEMALE; FOSTER CARE; HOSPITALIZATION; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TREATMENT DURATION; EPIDEMIOLOGY; POLYPHARMACY; PRESCRIPTION; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MEDICAID; POLYPHARMACY; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84906938685     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2014.05.010     Document Type: Article

References (50)

1. W.O. Cooper, P.G. Arbogast, H. Ding, G.B. Hickson, D.C. Fuchs, and W.A. Ray Trends in prescribing of antipsychotic medications for US children Ambul Pediatr 6 2006 79 83 (Pubitemid 43960577)
2. M. Matone, R. Localio, Y.S. Huang, S. dosReis, C. Feudtner, and D. Rubin The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children Health Serv Res 47 2012 1836 1860
3. M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje National trends in the outpatient treatment of children and adolescents with antipsychotic drugs Arch Gen Psychiatry 63 2006 679 685 (Pubitemid 43848299)
4. N.C. Patel, M.L. Crismon, and K. Hoagwood et al. Trends in the use of typical and atypical antipsychotics in children and adolescents J Am Acad Child Adolesc Psychiatry 44 2005 548 556 (Pubitemid 40720954)
5. J.M. Zito, M. Burcu, A. Ibe, D.J. Safer, and L.S. Magder Antipsychotic use by Medicaid-insured youths: impact of eligibility and psychiatric diagnosis across a decade Psychiatr Serv 64 2013 223 229
6. J.M. Zito, D.J. Safer, and S. DosReis et al. Psychotropic practice patterns for youth: a 10-year perspective Arch Pediatr Adolesc Med 157 2003 17 25 (Pubitemid 36343413)
7. M. Olfson, C. Blanco, S.M. Liu, S. Wang, and C.U. Correll National trends in the office-based treatment of children, adolescents, and adults with antipsychotics Arch Gen Psychiatry 69 2012 1247 1256
8. S.E. Andrade, J.C. Lo, and D. Roblin et al. Antipsychotic medication use among children and risk of diabetes mellitus Pediatrics 128 2011 1135 1141
9. C.U. Correll Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients Int Rev Psychiatry 20 2008 195 201 (Pubitemid 351489515)
10. C.U. Correll, and H.E. Carlson Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents J Am Acad Child Adolesc Psychiatry 45 2006 771 791 (Pubitemid 43932904)
11. C.U. Correll, P. Manu, V. Olshanskiy, B. Napolitano, J.M. Kane, and A.K. Malhotra Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents JAMA 302 2009 1765 1773
12. M. De Hert, M. Dobbelaere, E.M. Sheridan, D. Cohen, and C.U. Correll Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice Eur Psychiatry 26 2011 144 158
13. C. Panagiotopoulos, R. Ronsley, and J. Davidson Increased prevalence of obesity and glucose intolerance in youth treated with second-generation antipsychotic medications Canadian J Psychiatry 54 2009 743 749
14. D.J. Safer A comparison of risperidone-induced weight gain across the age span J Clin Psychopharmacol 24 2004 429 436 (Pubitemid 38944142)
15. L. Sikich, R.M. Hamer, R.A. Bashford, B.B. Sheitman, and J.A. Lieberman A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial Neuropsychopharmacology 29 2004 133 145 (Pubitemid 38068023)
16. J.S. Comer, M. Olfson, and R. Mojtabai National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007 J Am Acad Child Adolesc Psychiatry 49 2010 1001 1010
17. S. dosReis, J.M. Zito, D.J. Safer, J.F. Gardner, K.B. Puccia, and P.L. Owens Multiple psychotropic medication use for youths: a two-state comparison J Child Adolesc Psychopharmacol 15 2005 68 77 (Pubitemid 40365916)
18. J.M. Zito, D.J. Safer, and D. Sai et al. Psychotropic medication patterns among youth in foster care Pediatrics 121 2008 e157 e163
19. S. Pathak, E.S. Johns, and R.A. Kowatch Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: a case series J Child Adolesc Psychopharmacol 15 2005 696 702 (Pubitemid 41434374)
20. F.N. Emiroglu, O. Gencer, and A. Ozbek Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers. Four case reports Eur Child Adolesc Psychiatry 15 2006 500 503 (Pubitemid 46020535)
21. M.P. Delbello, M.L. Schwiers, H.L. Rosenberg, and S.M. Strakowski A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania J Am Acad Child Adolesc Psychiatry 41 2002 1216 1223 (Pubitemid 38338041)
22. V. Kafantaris, D.J. Coletti, R. Dicker, G. Padula, and J.M. Kane Adjunctive antipsychotic treatment of adolescents with bipolar psychosis J Am Acad Child Adolesc Psychiatry 40 2001 1448 1456 (Pubitemid 34250965)
23. M.N. Pavuluri, D.B. Henry, J.A. Carbray, G. Sampson, M.W. Naylor, and P.G. Janicak Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania J Affect Disord 82 Suppl 1 2004 S103 S111
24. G.L. Unwin, and S. Deb Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review Res Dev Disabil 32 2011 2121 2133
25. M.G. Aman, O.G. Bukstein, and K.D. Gadow et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry 53 2014 47 60
26. D. Linton, A.M. Barr, W.G. Honer, and R.M. Procyshyn Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability Curr Psychiatry Rep 15 2013 355
27. C.A. Colley, and L.M. Lucas Polypharmacy: the cure becomes the disease J Gen Intern Med 8 1993 278 283 (Pubitemid 23169392)
28. F.F. Duffy, W.E. Narrow, and D.S. Rae et al. Concomitant pharmacotherapy among youths treated in routine psychiatric practice J Child Adolesc Psychopharmacol 15 2005 12 25 (Pubitemid 40365910)
29. R.L. Dufresne Issues in polypharmacotherapy: focus on major depression Psychopharmacol Bull 32 1996 547 553 (Pubitemid 26428257)
30. D.A. Gorard Escalating polypharmacy Q J Med 99 2006 797 800 (Pubitemid 44688412)
31. S.J. Kingsbury, D. Yi, and G.M. Simpson Psychopharmacology: rational and irrational polypharmacy Psychiatr Serv 52 2001 1033 1036
32. I. Martínez-Mir, M. García-López, V. Palop, J.M. Ferrer, E. Rubio, and F.J. Morales-Olivas A prospective study of adverse drug reactions in hospitalized children Br J Clin Pharmacol 47 1999 681 688 (Pubitemid 29257667)
33. D.J. Safer, J.M. Zito, and S. DosReis Concomitant psychotropic medication for youths Am J Psychiatry 160 2003 438 449 (Pubitemid 41102118)
34. S.M. Stahl Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence? Int J Neuropsychopharmacol 7 2004 113 116 (Pubitemid 38823277)
35. S. Turner, A.J. Nunn, K. Fielding, and I. Choonara Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study Acta Paediatr 88 1999 965 968 (Pubitemid 29448261)
36. S. Crystal, M. Olfson, C. Huang, H. Pincus, and T. Gerhard Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges Health Aff 28 2009 w770 w781
37. C. Coyer, and G.M. Kenney The composition of children enrolled in Medicaid and CHIP: variation over time and by race and ethnicity 29 March 2013 Urban Institute Washington, DC
38. R. Raghavan, B.T. Zima, R.M. Andersen, A.A. Leibowitz, M.A. Schuster, and J. Landsverk Psychotropic medication use in a national probability sample of children in the child welfare system J Child Adolesc Psychopharmacol 15 2005 97 106 (Pubitemid 40365919)
39. J.M. Zito, D.J. Safer, I.H. Zuckerman, J.F. Gardner, and K. Soeken Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths Psychiatr Serv 56 2005 157 163 (Pubitemid 40216770)
40. S. dosReis, J.M. Zito, D.J. Safer, and K.L. Soeken Mental health services for youths in foster care and disabled youths Am J Public Health 91 2001 1094 1099 (Pubitemid 32574834)
41. V.L.H. Byrd, and A.H. Dodd Assessing the usability of encounter data for enrollees in comprehensive managed care across MAX 2007-2009 December 2012 Mathematica Policy Research Washington, DC
42. J. Nysenbaum, E. Bouchery, and R. Malsberger The availability and usability of behavioral health organization encounter data in MAX 2009 July 2013 Mathematica Policy Research Washington, DC
43. B.I. Graubard, and E.L. Korn Predictive margins with survey data Biometrics 55 1999 652 659 (Pubitemid 29302598)
44. A.L. Murphy, D.M. Gardner, C. Cooke, S. Kisely, J. Hughes, and S.P. Kutcher Prescribing trends of antipsychotics in youth receiving income assistance: results from a retrospective population database study BMC Psychiatry 13 2013 198
45. S. dosReis, Y. Yoon, D.M. Rubin, M.A. Riddle, E. Noll, and A. Rothbard Antipsychotic treatment among youth in foster care Pediatrics 128 2011 e1459 e1466
46. A.F. Garland, L. Brookman-Frazee, and M.S. Hurlburt et al. Mental health care for children with disruptive behavior problems: a view inside therapists' offices Psychiatr Serv 61 2010 788 795
47. Findling RL, Drury SS, Jensen PS, et al. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. In press.
48. W.V. Bobo, W.O. Cooper, and C.M. Stein et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth JAMA Psychiatry 70 2013 1067 1075
49. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes J Clin Psychiatry 65 2004 267 272
50. E.H. Morrato, G.E. Nicol, and D. Maahs et al. Metabolic screening in children receiving antipsychotic drug treatment Arch Pediatr Adolesc Med 164 2010 344 351